Taken in the context of previously published human studies showing elevated FGF21 levels in patients with metabolic syndrome and HFpEF9,23,24, we proposed that FGF21 signaling is a conserved critical mechanism contributing to pathological concentric hypertrophy and heart failure. The gene discussed is FGF21; the disease is metabolic syndrome.